Clomiphene is sold as a prescription drug for a reason: it has absolute contraindications, conditions requiring special care, and possible interactions with other drugs. The editors systematized these data based on official instructions and clinical guidelines.
Why know contraindications
Clomiphene is often perceived as a "light" drug that can be taken without special precautions. In fact, the official instructions contain a clear list of conditions in which the use is prohibited, and these restrictions have a physiological basis. They are related to how the drug is metabolized, which organs it acts on, and which processes it triggers.
Most of the contraindications are formulated for women, since clomiphene is registered for the induction of ovulation. However, a significant part of them logically applies to men who receive the drug outside of official indications: liver disease, organic brain damage, uncompensated endocrine disorders.
Knowledge of contraindications is also important because clomiphene often gets to people without a medical prescription. In such a situation, no clinician checks the medical history, orders tests or evaluates compatibility with other drugs — and that is when the risks become the highest.
Below, the editorial considers absolute contraindications from the instructions, conditions requiring special caution, and known or theoretically possible interactions with other means.
Absolute contraindications according to the instructions
The FDA-approved instruction manual for Clomid lists conditions in which clomiphene should not be used. The first is pregnancy: the drug does not have any therapeutic role during pregnancy, so before each course in women, it is excluded.
- hypersensitivity to clomiphene or excipients;
- pregnancy;
- liver disease or impaired liver function in history;
- uterine bleeding of unknown origin;
- ovarian cysts or enlargement not associated with polycystic ovary syndrome;
- uncompensated disorders of the function of the thyroid gland or adrenal glands;
- organic intracranial lesions, in particular pituitary tumors.
Liver diseases appear in the list because clomiphene is metabolized specifically in the liver and is excreted mainly with bile. Violation of these processes can change the concentration of the drug and increase the risk of unwanted reactions.
The requirement to exclude pituitary tumors and uncompensated endocrine disorders is related to the mechanism of action: clomiphene stimulates the hypothalamic-pituitary system. If the low level of sex hormones is caused by a tumor, hyperprolactinemia or hypothyroidism, stimulation will not only not correct the cause, but may also delay the correct diagnosis.
For men, this has a direct practical meaning: before prescribing clomiphene for secondary hypogonadism, the doctor usually evaluates prolactin, thyroid function, and, if indicated, prescribes an MRI of the pituitary gland.
Conditions requiring special care
In addition to absolute contraindications, there are situations where clomiphene is not prohibited directly, but its use requires careful evaluation. The most important of them is a history of visual impairment or the appearance of visual symptoms during treatment. The instructions require immediate discontinuation of the drug in case of blurred vision, flashes or scotomas, with prompt ophthalmological evaluation; visual impairment can occasionally persist.
The second group — thromboembolic complications in personal or family history. The SERM class is generally known to have an increased risk of venous thrombosis; although data are limited for clomiphene, doctors are mindful of this class risk in people with a predisposition to blood clots.
The third group — disorders of lipid metabolism, in particular hypertriglyceridemia. Estrogenic effects on the liver can increase the level of triglycerides, and isolated cases of their pronounced increase during clomiphene are described in the literature.
Finally, caution is needed with psychoemotional disorders: mood swings, irritability, and sleep disturbances are known side effects. For people with depression or anxiety, this is a strong argument for closer observation.
Interactions with other drugs
The official instructions note that no formal drug interaction studies have been conducted for clomiphene. This does not mean that there are no interactions, just that they have not been systematically studied. Therefore, most of the warnings have a pharmacological rather than an experimental basis.
| Medicine group | Possible interaction | Evidence level |
|---|---|---|
| Gonadotropins (in women) | Increased ovarian stimulation, risk of hyperstimulation | Clinically recognized |
| Estrogens, other SERMs | Competition for receptors, unpredictable cumulative effect | Theoretical |
| Aromatase inhibitors | Alteration of estradiol levels, additional effects on bone and lipids | Theoretical |
| Drugs with thrombogenic potential | Possible increased risk of thrombosis | Theoretical |
| Hepatotoxic agents, alcohol | Additional load on the liver | Theoretical |
In the sports environment, clomiphene is often combined with anabolic steroids, aromatase inhibitors, and other substances. Such combinations have not been studied under controlled conditions, so their safety is unknown and the risks may add up.
Oral 17-alpha-alkylated steroids, which have their own hepatotoxicity, should be mentioned separately. The combination with a drug that is metabolized in the liver and is contraindicated in liver diseases creates an additional burden on this organ.
The doctor should always be informed of all drugs and supplements that a person takes, including herbal remedies and sports nutrition. This allows you to assess the real risks, not just those indicated in the instructions.
Clomiphene and sports: legal aspect
Contraindications have not only a medical, but also a regulatory dimension. Clomiphene is included in the Prohibited List of WADA in the section of hormonal and metabolic modulators, among anti-estrogenic substances. The ban is in effect at all times, both during and outside of competitions.
For an athlete subject to doping control, this is essentially another “contraindication”: use without a therapeutic use exemption (TUE) is an anti-doping rule violation regardless of purpose or dose.
If clomiphene is medically necessary, such as infertility, the athlete must contact their National Anti-Doping Organization or International Federation for a TUE. The procedure involves documentary confirmation of the diagnosis and justification of the absence of alternatives.
It's also worth remembering that some products marketed as "testosterone boosters" may contain undeclared SERMs. It is safer for an athlete to choose products that have passed independent sport-specific batch testing, while recognizing that testing cannot eliminate every risk.
Editorial conclusions
Clomiphene has clear contraindications: pregnancy, liver disease, organic lesions of the brain and pituitary tumors, uncompensated disorders of the thyroid gland and adrenal glands, and for women - unexplained bleeding and ovarian cysts.
There are no systematic studies of interactions, so caution when combining with other hormonal agents is based on pharmacology. Special attention should be paid to thrombosis in the anamnesis, disorders of lipid metabolism, psychoemotional disorders and any visual symptoms.
Only a doctor who has access to the anamnesis and test results can assess all these factors. Self-use without such an assessment deprives a person of the main protective mechanism.
The editors advise you to also read our materials about the side effects of clomiphene, about the myths surrounding this drug and about the mechanism of action of enclomiphene.
References
- Clomid (clomiphene citrate tablets USP). Prescribing information. U.S. Food and Drug Administration.
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744.
- Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200(2):423–432.
- Katz DJ, Nabulsi O, Tal R, Mulhall JP. Outcomes of clomiphene citrate treatment in young hypogonadal men. BJU Int. 2012;110(4):573–578.
- Krzastek SC, Sharma D, Abdullah N, et al. Long-term safety and efficacy of clomiphene citrate for the treatment of hypogonadism. J Urol. 2019;202(5):1029–1035.
- Pope HG Jr, Wood RI, Rogol A, et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35(3):341–375.
- World Anti-Doping Agency. The World Anti-Doping Code International Standard: Prohibited List. Montreal: WADA; акÑÑалÑна ÑедакÑÑÑ.
